Newsroom — launching after verification

No articles are published yet. Seed topics under primary-source verification include: 2026 FDA enforcement and warning letters concerning telehealth marketing of compounded GLP-1 drugs; FDA's April 30, 2026 proposal on semaglutide, tirzepatide, and liraglutide and the 503B bulks list; adverse-event reporting totals for compounded products; provider pricing and pharmacy changes; manufacturer cash-pay program changes; coverage developments; recalls; and retatrutide phase 3 status (research-only — retatrutide is not FDA approved and is not lawfully available as a compounded treatment). Each article will separate event date, publication date, discovery date, and last-updated date, cite primary sources, and carry a visible change log.